{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:05:22Z","timestamp":1791137122637,"version":"4.1.0"},"reference-count":144,"publisher":"European Respiratory Society (ERS)","issue":"161","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2021,5,1]]},"published-print":{"date-parts":[[2021,9,30]]},"abstract":"<jats:p>Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory infection associated with declining lung function, radiological deterioration and significantly increased morbidity and mortality. Patients often have underlying lung conditions, particularly bronchiectasis and COPD. NTM pulmonary disease is difficult to treat because mycobacteria can evade host defences and antimicrobial therapy through extracellular persistence in biofilms and sequestration into macrophages. Management of NTM pulmonary disease remains challenging and outcomes are often poor, partly due to limited penetration of antibiotics into intracellular spaces and biofilms. Efficient drug delivery to the site of infection is therefore a key objective of treatment, but there is high variability in lung penetration by antibiotics. Inhalation is the most direct route of delivery and has demonstrated increased efficacy of antibiotics like amikacin compared with systemic administration. Liposomes are small, artificial, enclosed spherical vesicles, in which drug molecules can be encapsulated to provide controlled release, with potentially improved pharmacokinetics and reduced toxicity. They are especially useful for drugs where penetration of cell membranes is essential. Inhaled delivery of liposomal drug solutions can therefore facilitate direct access to macrophages in the lung where the infecting NTM may reside. A range of liposomal drugs are currently being evaluated in respiratory diseases.<\/jats:p>","DOI":"10.1183\/16000617.0010-2021","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T06:50:50Z","timestamp":1626850250000},"page":"210010","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections"],"prefix":"10.1183","volume":"30","author":[{"given":"James D.","family":"Chalmers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-2003","authenticated-orcid":false,"given":"Jakko","family":"van Ingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roald","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2347-6418","authenticated-orcid":false,"given":"Jean-Louis","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"2024102403560413000_30.161.210010.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00250-2019"},{"key":"2024102403560413000_30.161.210010.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.09.007"},{"key":"2024102403560413000_30.161.210010.3","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0148"},{"key":"2024102403560413000_30.161.210010.4","first-page":"e008058","article-title":"Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular\/bronchiectatic Mycobacterium avium complex lung disease","volume":"5","author":"Gochi","year":"2015","journal-title":"Respir Med"},{"key":"2024102403560413000_30.161.210010.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.06.005"},{"key":"2024102403560413000_30.161.210010.6","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3113-x"},{"key":"2024102403560413000_30.161.210010.7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12890-020-1165-3","article-title":"Longitudinal changes in health-related quality of life according to clinical course among patients with non-tuberculous mycobacterial pulmonary disease: a prospective cohort study","volume":"20","author":"Kwak","year":"2020","journal-title":"BMC Pulm Med"},{"key":"2024102403560413000_30.161.210010.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2017.10.013"},{"key":"2024102403560413000_30.161.210010.9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.meegid.2019.01.017","article-title":"Nontuberculous mycobacteria: insights on taxonomy and evolution","volume":"72","author":"Turenne","year":"2019","journal-title":"Infect Genet Evol"},{"key":"2024102403560413000_30.161.210010.10","doi-asserted-by":"publisher","DOI":"10.1099\/ijsem.0.003026"},{"key":"2024102403560413000_30.161.210010.11","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00149212"},{"key":"2024102403560413000_30.161.210010.12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1055\/s-0038-1660864","article-title":"Geographic distribution of nontuberculous mycobacteria isolated from clinical specimens: a systematic review","volume":"39","author":"Zweijpfenning","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"key":"2024102403560413000_30.161.210010.13","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00899-13"},{"key":"2024102403560413000_30.161.210010.14","doi-asserted-by":"publisher","DOI":"10.1007\/s40572-016-0086-z"},{"key":"2024102403560413000_30.161.210010.15","doi-asserted-by":"crossref","unstructured":"van Ingen J , Griffith DE , Aksamit TR , et al. Pulmonary diseases caused by non-tuberculous mycobacteria. In: Lange C , Migliori GB , eds. Tuberculosis (ERS Monograph). Sheffield, European Respiratory Society, 2012; pp. 25\u201337. doi:10.1183\/1025448x.10022511","DOI":"10.1183\/1025448x.10022511"},{"key":"2024102403560413000_30.161.210010.16","first-page":"105889","article-title":"Real-life evaluation of clinical outcomes in patients undergoing treatment for non-tuberculous mycobacteria lung disease: a ten-year cohort study","volume":"64","author":"Aliberti","year":"2020","journal-title":"Respir Med"},{"key":"2024102403560413000_30.161.210010.17","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2008.110957"},{"key":"2024102403560413000_30.161.210010.18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.rmed.2017.08.031","article-title":"Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort","volume":"131","author":"Zweijpfenning","year":"2017","journal-title":"Respir Med"},{"key":"2024102403560413000_30.161.210010.19","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209729"},{"key":"2024102403560413000_30.161.210010.20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","article-title":"Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus","volume":"18","author":"Johansen","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"2024102403560413000_30.161.210010.21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01102-2015"},{"key":"2024102403560413000_30.161.210010.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmyco.2014.11.065"},{"key":"2024102403560413000_30.161.210010.23","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00820-13"},{"key":"2024102403560413000_30.161.210010.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2422-8"},{"key":"2024102403560413000_30.161.210010.25","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2018-0249"},{"key":"2024102403560413000_30.161.210010.26","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.4049\/jimmunol.140.9.3006","article-title":"Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex","volume":"140","author":"Bermudez","year":"1988","journal-title":"J Immunol"},{"key":"2024102403560413000_30.161.210010.27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12890-016-0185-5","article-title":"Mycobacteria infect different cell types in the human lung and cause species dependent cellular changes in infected cells","volume":"16","author":"Ganbat","year":"2016","journal-title":"BMC Pulm Med"},{"key":"2024102403560413000_30.161.210010.28","doi-asserted-by":"crossref","first-page":"37804","DOI":"10.1038\/srep37804","article-title":"Mycobacterium avium MAV2054 protein induces macrophage apoptosis by targeting mitochondria and reduces intracellular bacterial growth","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep"},{"key":"2024102403560413000_30.161.210010.29","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00548-2020"},{"key":"2024102403560413000_30.161.210010.30","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00590-2020"},{"key":"2024102403560413000_30.161.210010.31","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00739-17"},{"key":"2024102403560413000_30.161.210010.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-1229(05)80026-1"},{"key":"2024102403560413000_30.161.210010.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2014.07.009"},{"key":"2024102403560413000_30.161.210010.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2014.07.001"},{"key":"2024102403560413000_30.161.210010.35","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.65.9.3759-3767.1997"},{"key":"2024102403560413000_30.161.210010.36","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.64.6.2256-2261.1998"},{"key":"2024102403560413000_30.161.210010.37","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.160185"},{"key":"2024102403560413000_30.161.210010.38","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.02032-14"},{"key":"2024102403560413000_30.161.210010.39","doi-asserted-by":"publisher","DOI":"10.1128\/jb.178.2.456-461.1996"},{"key":"2024102403560413000_30.161.210010.40","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/iai.58.8.2564-2568.1990","article-title":"Characterisation and growth in human macrophages of Mycobacterium avium complex strains isolated from the blood of patients with acquired immunodeficiency syndrome","volume":"58","author":"Meylan","year":"1990","journal-title":"Infect Immun"},{"key":"2024102403560413000_30.161.210010.41","doi-asserted-by":"publisher","DOI":"10.1128\/JB.185.16.5003-5006.2003"},{"key":"2024102403560413000_30.161.210010.42","doi-asserted-by":"publisher","DOI":"10.1111\/mmi.12387"},{"key":"2024102403560413000_30.161.210010.43","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00835-06"},{"key":"2024102403560413000_30.161.210010.44","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02592-06"},{"key":"2024102403560413000_30.161.210010.45","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1128\/iai.59.6.2207-2214.1991","article-title":"Intramacrophage growth of Mycobacterium avium during infection of mice","volume":"59","author":"Frehel","year":"1991","journal-title":"Infect Immun"},{"key":"2024102403560413000_30.161.210010.46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2012.01799.x"},{"key":"2024102403560413000_30.161.210010.47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/microorganisms7050113","article-title":"Nontuberculous mycobacteria persistence in a cell model mimicking alveolar macrophages","volume":"7","author":"Sousa","year":"2019","journal-title":"Microoganisms"},{"key":"2024102403560413000_30.161.210010.48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1713195115"},{"key":"2024102403560413000_30.161.210010.49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.15698\/mic2019.02.667","article-title":"The extracellular matrix of mycobacterial biofilms: could we shorten the treatment of mycobacterial infections?","volume":"4","author":"Chakraborty","year":"2019","journal-title":"Microb Cell"},{"key":"2024102403560413000_30.161.210010.50","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3389\/fmicb.2017.02651","article-title":"Mycobacterium biofilms","volume":"8","author":"Esteban","year":"2018","journal-title":"Front Microbiol"},{"key":"2024102403560413000_30.161.210010.51","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/809014"},{"key":"2024102403560413000_30.161.210010.52","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fux010"},{"key":"2024102403560413000_30.161.210010.53","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2013.12.24"},{"key":"2024102403560413000_30.161.210010.54","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.01633-06"},{"key":"2024102403560413000_30.161.210010.55","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01212-19"},{"key":"2024102403560413000_30.161.210010.56","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00986-07"},{"key":"2024102403560413000_30.161.210010.57","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.5.1186"},{"key":"2024102403560413000_30.161.210010.58","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.2.8756832"},{"key":"2024102403560413000_30.161.210010.59","doi-asserted-by":"publisher","DOI":"10.1126\/science.1279810"},{"key":"2024102403560413000_30.161.210010.60","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05030-11"},{"key":"2024102403560413000_30.161.210010.61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pulmoe.2017.12.005","article-title":"Non-tuberculous mycobacterial pulmonary infections","volume":"24","author":"Chalmers","year":"2018","journal-title":"Pulmonology"},{"key":"2024102403560413000_30.161.210010.62","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.14.60"},{"key":"2024102403560413000_30.161.210010.63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005660"},{"key":"2024102403560413000_30.161.210010.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2009.12.007"},{"key":"2024102403560413000_30.161.210010.65","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01275-08"},{"key":"2024102403560413000_30.161.210010.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2012.04.001"},{"key":"2024102403560413000_30.161.210010.67","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3389\/fmicb.2018.00915","article-title":"Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Microbiol"},{"key":"2024102403560413000_30.161.210010.68","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00535-2020"},{"key":"2024102403560413000_30.161.210010.69","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-2538"},{"key":"2024102403560413000_30.161.210010.70","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14787210.2020.1720650","article-title":"Antibiotic therapy success in pulmonary Mycobacterium avium complex: a systematic review and meta-analysis","volume":"18","author":"Nasiri","year":"2020","journal-title":"Exp Rev Anti Ther"},{"key":"2024102403560413000_30.161.210010.71","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12931-019-1258-9","article-title":"Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis","volume":"20","author":"Park","year":"2019","journal-title":"Respir Res"},{"key":"2024102403560413000_30.161.210010.72","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw724"},{"key":"2024102403560413000_30.161.210010.73","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01991-2018"},{"key":"2024102403560413000_30.161.210010.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.019"},{"key":"2024102403560413000_30.161.210010.75","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00133-06"},{"key":"2024102403560413000_30.161.210010.76","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2014.46.4.219"},{"key":"2024102403560413000_30.161.210010.77","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz143"},{"key":"2024102403560413000_30.161.210010.78","doi-asserted-by":"publisher","DOI":"10.1177\/0885066618754784"},{"key":"2024102403560413000_30.161.210010.79","doi-asserted-by":"publisher","DOI":"10.2174\/1381612823666161116114732"},{"key":"2024102403560413000_30.161.210010.80","doi-asserted-by":"publisher","DOI":"10.4155\/tde.13.71"},{"key":"2024102403560413000_30.161.210010.81","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/molecules23020288","article-title":"Liposomes: clinical applications and potential for image-guided drug delivery","volume":"23","author":"Lamichhane","year":"2018","journal-title":"Molecules"},{"key":"2024102403560413000_30.161.210010.82","first-page":"49","article-title":"Clinical development of liposome based drugs: formulation, characterization, and therapeutic efficacy","volume":"7","author":"Chang","year":"2012","journal-title":"Int J Nanomed"},{"key":"2024102403560413000_30.161.210010.83","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00286"},{"key":"2024102403560413000_30.161.210010.84","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2016.1177136"},{"key":"2024102403560413000_30.161.210010.85","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fimmu.2018.00155","article-title":"The multirole of liposomes in therapy and prevention of infectious diseases","volume":"9","author":"Nisini","year":"2018","journal-title":"Front Immunol"},{"key":"2024102403560413000_30.161.210010.86","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn059"},{"key":"2024102403560413000_30.161.210010.87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108703"},{"key":"2024102403560413000_30.161.210010.88","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4172\/2155-952X.1000276","article-title":"Liposomes for drug delivery","volume":"7","author":"Yadav","year":"2017","journal-title":"J Biotechnol Biomater"},{"key":"2024102403560413000_30.161.210010.89","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.2147\/IJN.S192219","article-title":"Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutics effect of quercetin in lung cancer therapy","volume":"24","author":"Riaz","year":"2019","journal-title":"Int J Nanomed"},{"key":"2024102403560413000_30.161.210010.90","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2019.04.003","article-title":"Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors","volume":"132","author":"Cui","year":"2019","journal-title":"Lung Cancer"},{"key":"2024102403560413000_30.161.210010.91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/bbrj.bbrj_54_17","article-title":"Liposomes as potential nanocarriers for theranostic applications in chronic inflammatory lung diseases","volume":"1","author":"Suer","year":"2017","journal-title":"Biomed Biotechnol Res J"},{"key":"2024102403560413000_30.161.210010.92","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000445116","article-title":"Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications","volume":"25","author":"Rudokas","year":"2016","journal-title":"Med Princ Pract"},{"key":"2024102403560413000_30.161.210010.93","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40265-020-01359-z","article-title":"Inhaled liposomal antimicrobial delivery in lung infections","volume":"80","author":"Bassetti","year":"2020","journal-title":"Drugs"},{"key":"2024102403560413000_30.161.210010.94","first-page":"CD010481","article-title":"Amphotericin B deoxycholate versus liposomal amphoteracin B: effects on kidney function","volume":"11","author":"Botero Aguirre","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102403560413000_30.161.210010.95","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4155\/tde.10.8","article-title":"Controlled subcellular delivery to optimize therapeutic effect","volume":"1","author":"Mossalam","year":"2010","journal-title":"Ther Deliv"},{"key":"2024102403560413000_30.161.210010.96","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.8.1179"},{"key":"2024102403560413000_30.161.210010.97","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/156.3.510"},{"key":"2024102403560413000_30.161.210010.98","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(90)90079-N"},{"key":"2024102403560413000_30.161.210010.99","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1473-3099(19)30574-2","article-title":"Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial","volume":"20","author":"Niederman","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2024102403560413000_30.161.210010.100","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.3.333"},{"key":"2024102403560413000_30.161.210010.101","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/jamp.2017.1415","article-title":"The rationale and evidence for use of inhaled antibiotics to control Pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis","volume":"31","author":"Dhand","year":"2018","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2024102403560413000_30.161.210010.102","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.07024"},{"key":"2024102403560413000_30.161.210010.103","doi-asserted-by":"crossref","first-page":"2732017","DOI":"10.1155\/2018\/2732017","article-title":"Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes","volume":"2018","author":"Borghardt","year":"2018","journal-title":"Can Respir J"},{"key":"2024102403560413000_30.161.210010.104","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.6.562"},{"key":"2024102403560413000_30.161.210010.105","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051062"},{"key":"2024102403560413000_30.161.210010.106","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/CCM.0000000000002695","article-title":"Nebulized versus IV amikacin as adjunctive antibiotic for hospital and ventilator-acquired pneumonia postcardiac surgeries: a randomized controlled trial","volume":"46","author":"Hassan","year":"2018","journal-title":"Crit Care Med"},{"key":"2024102403560413000_30.161.210010.107","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.04208"},{"key":"2024102403560413000_30.161.210010.108","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-011-2420-0"},{"key":"2024102403560413000_30.161.210010.109","doi-asserted-by":"publisher","DOI":"10.1177\/1753465817691239"},{"key":"2024102403560413000_30.161.210010.110","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis","volume":"7","author":"Laska","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024102403560413000_30.161.210010.111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2009.04.005"},{"key":"2024102403560413000_30.161.210010.112","doi-asserted-by":"publisher","DOI":"10.2741\/3627"},{"key":"2024102403560413000_30.161.210010.113","first-page":"104","article-title":"Emerging opportunities for inhaled antibiotic therapy","volume":"1","author":"Cipolla","year":"2015","journal-title":"J Antimicro"},{"key":"2024102403560413000_30.161.210010.114","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2018-0194"},{"key":"2024102403560413000_30.161.210010.115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infections with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024102403560413000_30.161.210010.116","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.cmi.2019.04.017","article-title":"Microbiological changes observed over 48\u2005weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection","volume":"25","author":"van Devanter","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2024102403560413000_30.161.210010.117","doi-asserted-by":"crossref","first-page":"1753466619875930","DOI":"10.1177\/1753466619875930","article-title":"Efficacy of inhaled ciprofloxacin agents for the treatment of bronchiectasis: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Lim","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"2024102403560413000_30.161.210010.118","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00440-18"},{"key":"2024102403560413000_30.161.210010.119","unstructured":"Electronic Medicines Compendium (EMC) . Amikacin 250\u2005mg\/ml Injection. Hospira UK Ltd. www.medicines.org.uk\/emc\/product\/3784\/smpc Date last accessed: March 2020. Date last updated: 26 April 2021."},{"key":"2024102403560413000_30.161.210010.120","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02282-15"},{"key":"2024102403560413000_30.161.210010.121","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201204-0682OC"},{"key":"2024102403560413000_30.161.210010.122","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01050-15"},{"key":"2024102403560413000_30.161.210010.123","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.7.1549"},{"key":"2024102403560413000_30.161.210010.124","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2008.0686"},{"key":"2024102403560413000_30.161.210010.125","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00700-16"},{"key":"2024102403560413000_30.161.210010.126","first-page":"A3732","article-title":"Airway deposition and retention of liposomal amikacin for inhalation in patients with pulmonary nontuberculous mycobacterial disease","volume":"193","author":"Olivier","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403560413000_30.161.210010.127","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40265-019-01095-z","article-title":"Amikacin liposome inhalation suspension: a review in Mycobacterium avium complex lung disease","volume":"79","author":"Shirley","year":"2019","journal-title":"Drugs"},{"key":"2024102403560413000_30.161.210010.128","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2008.0693"},{"key":"2024102403560413000_30.161.210010.129","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0700OC"},{"key":"2024102403560413000_30.161.210010.130","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1318OC"},{"key":"2024102403560413000_30.161.210010.131","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2019.OA4951"},{"key":"2024102403560413000_30.161.210010.132","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13318-020-00669-7","article-title":"Population pharmacokinetic evaluation of amikacin liposome inhalation suspension in patients with treatment-refractory nontuberculous mycobacterial lung disease","volume":"46","author":"Rubino","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2024102403560413000_30.161.210010.133","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QCO.0000000000000525","article-title":"Why have trials of inhaled antibiotics for ventilator-associated infections failed?","volume":"32","author":"Palmer","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"2024102403560413000_30.161.210010.134","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.cmi.2019.04.018","article-title":"Why don't we have more inhaled antibiotics to treat ventilator-associated pneumonia?","volume":"25","author":"Sweeney","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2024102403560413000_30.161.210010.135","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.05.013"},{"key":"2024102403560413000_30.161.210010.136","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/j.jcf.2019.04.017","article-title":"Use of inhaled imipenem\/cilastatin in pediatric patients with cystic fibrosis: a case series","volume":"18","author":"Jones","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2024102403560413000_30.161.210010.137","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/jac\/dkaa110","article-title":"Inhaled tigecycline is effective against Mycobacterium abscessus in vitro and in vivo","volume":"75","author":"Pearce","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024102403560413000_30.161.210010.138","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv180"},{"key":"2024102403560413000_30.161.210010.139","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku431"},{"key":"2024102403560413000_30.161.210010.140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph12010001","article-title":"Decrease of antimicrobial resistance through polyelectrolyte-coated nanoliposomes loaded with \u03b2-lactam drug","volume":"12","author":"Ar\u00e9valo","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"2024102403560413000_30.161.210010.141","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02204-2019"},{"key":"2024102403560413000_30.161.210010.142","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3389\/fmicb.2018.02813","article-title":"Assessing response to therapy for nontuberculous mycobacterial lung disease: quo vadis?","volume":"9","author":"Vinnard","year":"2018","journal-title":"Front Microbiol"},{"key":"2024102403560413000_30.161.210010.143","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00011815"},{"key":"2024102403560413000_30.161.210010.144","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01300-2019"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0010-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:03:17Z","timestamp":1740373397000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0010-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":144,"journal-issue":{"issue":"161","published-online":{"date-parts":[[2021,7,20]]},"published-print":{"date-parts":[[2021,9,30]]}},"alternative-id":["10.1183\/16000617.0010-2021"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0010-2021","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]}}}